Abstracts tagged "Mortality"

Abstract Number: 0884 • ACR Convergence 2025
Risk Score for Early Mortality to stratify for Intensive SSc Therapy
Ann-Christin Pecher¹, Boubaya Marouane², Oliver Distler³, Vanessa Smith⁴, Jeska de Vries-Bouwstra⁵, Radim Bečvář⁶, Gianluca Moroncini⁷, David Launay⁸, Yannick Allanore⁹, Maria De Santis¹⁰, Kamal Solanki¹¹, Carlomaurizio Montecucco¹², Luca Idolazzi¹³, Nihal Fathi¹⁴, Przemyslaw Kotyla¹⁵, Muriel Elhai¹⁶ and Jörg Henes¹⁷, ¹Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, ²Unit of Clinical Research, Paris Seine Saint Denis University, Bobigny, France, Paris, France, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Internal Medicine, Charles University,, Prague, Czech Republic, ⁷Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁸Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille France, Lille, France, ⁹Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France, ¹⁰Humanitas University, Pieve Emanuele, Italy, ¹¹Waikato Hospital, Hamilton, New Zealand, ¹²Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, Pavia, Italy, ¹³Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy, Verona, Italy, ¹⁴Department of Rheumatology ,Rehabilitation & physical medicine, Assiut University Hospital, Assiut, Egypt, Assiut, Egypt, ¹⁵Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland, ¹⁶University Hospital zurich, Zürich, Switzerland, ¹⁷Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a rare disease that often leads to severe complications and premature mortality. Recent advancements in the field have led to…
Abstract Number: 2412 • ACR Convergence 2025
Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
Maria Romero Noboa¹, Faria Sami², Almurtada Razok³ and Shahzad Ahmed Sami⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²The University of Alabama at Birmingham, Birmingham, AL, ³John H Stroger Jr Hospital of Cook County, Chicago, IL, ⁴DCH Regional Medical Center, Birmingham
Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare manifestation of Systemic Lupus Erythematosus (SLE) with increased morbidity and mortality. It has historically been underdiagnosed in…
Abstract Number: 1881 • ACR Convergence 2025
Silent Impact: Two Decades of Sjögren’s Syndrome Mortality in the United States
Aziz-ur-Rahman Khalid¹, Ghassan Makhoul², Hasan Munshi², Islam Rajab², MD Walid Akram Hussain², Reshma John², Elvira Assaf², Amer Al Badawy², Barbare Khatiashvili², Rouba Isshak², John Salama², Ibrahim Sabah² and Robert Lahita³, ¹St. Joseph's University Medical Center, wayne, ²St. Josephs University Medical Center, Paterson, ³St. Josephs University Medical Center, Wayne, NJ
Background/Purpose: Sjögren’s syndrome is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands with potential systemic involvement. Despite its known complications, population-level mortality…
Abstract Number: 1187 • ACR Convergence 2025
Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Tulaton Sodsri¹, Nattanicha Chaisrimaneepan², Ben Thiravetyan³, Rabhas Boonyawairote⁴, Nopavit Mohpichai⁵, Nutchapon Xanthavanij⁶, Natnicha Jakramonpreeya⁷, Pintip Ngamjanyaporn⁸ and Tananchai Petnak⁸, ¹Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, ⁴University of Illinois at Chicago, Chicago, ⁵Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁶Mount Auburn Hospital, Harvard Medical School, Cambridge, ⁷Chakri Naruebodindra Medical Institute, Bangkok, Thailand, ⁸Ramathibodi Hospital, Bangkok, Thailand
Background/Purpose: The associations between various myositis-specific antibodies (MSAs), rapidly progressive interstitial lung disease (RP-ILD), and mortality in antisynthetase syndrome (ASS) have been previously reported in…
Abstract Number: 0806 • ACR Convergence 2025
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Teng-Chieh Hsu¹, An-Ping Huo², Pei-Lun Liao², Pui-Ying Leong² and James Wei³, ¹Wuri Lin Shin Hospital, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China)
Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…
Abstract Number: 0695 • ACR Convergence 2024
Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Stefano Di Donato¹, Marco Minerba², Enrico De Lorenzis³, Collette Hartley⁴, Lesley-Anne Bissell⁵, Rebecca Ross⁶ and Francesco Del Galdo⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Campus Bio-Medico University of Rome, Taranto, United Kingdom, ³Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
Abstract Number: 1614 • ACR Convergence 2024
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez-Álvaro², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maite Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael Gonzalez⁷, Julio Sánchez-Martín⁸, Javier Narvaez-García⁹, Joan Calvet¹⁰, Ivette Casafont-Solé¹¹, José A Román Ivorra¹², Selene Labrada-Arrabal¹³, Margarida Vasques Rocha:¹⁴, Carlota L Iñiguez:¹⁵, Maria Sagrario Bustabad Reyes¹⁶, Cristina Campos-Fernández¹⁷, María Alcalde Villar:¹⁸, Antonio Juan-Mas¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Ourense, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, ⁷Complejo Asistencial Universitario de Leon, León, Spain, ⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valencia, Spain, Valencia, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital Universitario Araba, Vitoria, Spain, ¹⁵Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁶Hospital Universitario de Canarias, La Laguna - Tenerife, Spain, ¹⁷Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ¹⁸Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Mallorca, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: The question of survival in epidemiologic studies on giant cell arteritis (GCA) remains unclear to date, with notable heterogeneity in both the mortality rate…
Abstract Number: 2393 • ACR Convergence 2024
Demographic Differences in Trends of Systemic Lupus Erythematosus In-hospital Patient Outcomes
Joan Morny¹, Abdultawab Shaka², Terrylyna Baffoe-Bonnie³ and Hafeez Shaka⁴, ¹Piedmont Athens Regional Medical Center, athens, GA, ²Windor University School of Medicine, Saint Kitts and Nevis, U.S. Virgin Islands, ³Medstar Health Union Memorial Hospital, Baltimore, MD, ⁴Stroger Jr Hospital, Chicago, IL
Background/Purpose: The care of patients with Systemic Lupus Erythematosus (SLE) is challenging, and with the emergency of newer disease modifying medications, clinical outcomes in these…
Abstract Number: 0142 • ACR Convergence 2024
The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis
Nidaa Rasheed¹, kHALED ABDULLAH² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Gout is characterized by chronic inflammatory arthritis caused by the deposition of monosodium urate crystals and leads to increased risk of complications, such as…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…
Abstract Number: 1715 • ACR Convergence 2024
Mortality Trends for Systemic Connective Tissue Diseases Across the United States from 1999 to 2020: A CDC-Wonder Database Analysis
Naima Khan¹, Yumna Furqan², Madiha Salman¹, Eman Ali¹, Wajeeh ur Rehman³, Ibtesam Allahi⁴, Farah Yasmin⁵ and Muhammad Sohaib Asghar⁶, ¹Dow University of Health Sciences, Karachi, Pakistan, ²Texas A&M School of Medicine, Dallas, TX, ³University Health Services Hospital, Johnson, NY, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, ⁶AdventHealth, Sebring, FL
Background/Purpose: The mortality burden of systemic connective tissue diseases (CTDs) is expected to rise in the U.S population because of multimorbidity and ageing. The primary…
Abstract Number: 2406 • ACR Convergence 2024
Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes
Sai Yasaswini Kommaraju¹, Liza Rajasekhar², Ashish J Mathew³, Vineeta Shobha⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Able Lawrence⁷, Bidyut Das⁸, Manish Rathi⁹, Ranjan Gupta¹⁰, Avinash Jain¹¹ and Amita Aggarwal¹², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ³Christian Medical College, Vellore, Tamil Nadu, India, ⁴St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁵Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁸SCB Medical College, Cuttack, Orissa, India, ⁹Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹⁰All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹¹Sawai Man Singh Hospital, Lucknow, Rajasthan, India, ¹²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) has a significant impact on morbidity associated with SLE. However, the prevalence of NPSLE has been reported variably based…
Abstract Number: 0173 • ACR Convergence 2024
Systemic Lupus Erythematosus Mortality—United States, 2018–2022
Danielle Dawson¹, Kurt Greenlund² and Kamil Barbour², ¹CDC, Atlanta, GA, ²CDC, Alpharetta, GA
Background/Purpose: Mortality due to cardiovascular disease, infections, and renal disease is elevated in people with systemic lupus erythematosus (SLE) compared with the general population, but…
Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…

« Previous Page
1
…
3
4
5
6
7
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].